Recce Pharmaceuticals Ltd. (AU:RCE)
ASX:RCE
Want to see AU:RCE full AI Analyst Report?
RCE Stock Chart & Stats
AU$0.41
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.41
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.29 - AU$0.73
Previous CloseN/A
Volume21.12K
Average Volume (3M)154.69K
Market Cap
AU$138.81M
Enterprise ValueAU$158.38M
Total Cash (Recent Filing)AU$602.99K
Total Debt (Recent Filing)AU$11.26M
Price to Earnings (P/E)―
Beta0.97
Next Earnings
Aug 28, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.12
Shares Outstanding289,183,400
10 Day Avg. Volume112,630
30 Day Avg. Volume154,688
Financial Highlights & Ratios
PEG Ratio0.34
Price to Book (P/B)-22.52
Price to Sales (P/S)9.15
P/FCF Ratio-3.36
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.06
Revenue Forecast (FY)AU$4.25M
Bulls Say, Bears Say
Bulls Say
Free Cash Flow GrowthA 51.97% free cash flow growth rate indicates improving cash generation versus prior periods. Over a 2-6 month horizon this strengthens runway for clinical programs, reduces near-term dilution needs, and provides more financial flexibility to fund R&D or regulatory activities.
Free Cash Flow AlignmentFree cash flow roughly tracking net income suggests losses include cash components rather than being dominated by non-cash charges. That makes cash burn more predictable, aiding realistic runway planning and lowering the structural unpredictability of financing needs.
Strategic Pipeline Addressing ResistanceRecce's focus on novel broad-spectrum agents against antibiotic-resistant pathogens targets a durable, underserved market with high entry barriers. Multiple formulations (IV, oral, topical) diversify commercial pathways and materially enhance long-term addressable market if clinical progress continues.
Bears Say
Revenue DeclineA 21.73% decline in revenue signals weakening top-line momentum, reducing internal funding capacity for costly clinical and regulatory programs. Over months this increases dependence on external capital, pressures operating plans, and limits ability to scale or commercialize without further financing.
Severe Negative MarginsExtremely negative net and EBIT margins indicate the business is incurring losses many times revenue, reflecting unsustainable burn relative to current scale. Persisting such margins would deplete resources quickly and necessitate significant funding or operational restructuring to reach sustainable economics.
Balance Sheet Weakness / Negative EquityNegative equity and a debt-to-equity of -3.53 constrain financing options and raise creditor and covenant risk. Structurally this increases the likelihood of dilutive capital raises or restrictive financing terms, limiting strategic flexibility and elevating survival risk absent material cash generation improvements.
Recce Pharmaceuticals Ltd. News
RCE FAQ
What was Recce Pharmaceuticals Ltd.’s price range in the past 12 months?
Recce Pharmaceuticals Ltd. lowest share price was AU$0.28 and its highest was AU$0.73 in the past 12 months.
What is Recce Pharmaceuticals Ltd.’s market cap?
Recce Pharmaceuticals Ltd.’s market cap is AU$138.81M.
When is Recce Pharmaceuticals Ltd.’s upcoming earnings report date?
Recce Pharmaceuticals Ltd.’s upcoming earnings report date is Aug 28, 2026 which is in 67 days.
How were Recce Pharmaceuticals Ltd.’s earnings last quarter?
Recce Pharmaceuticals Ltd. released its earnings results on Feb 27, 2026. The company reported -AU$0.057 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.057.
Is Recce Pharmaceuticals Ltd. overvalued?
According to Wall Street analysts Recce Pharmaceuticals Ltd.’s price is currently Overvalued.
Does Recce Pharmaceuticals Ltd. pay dividends?
Recce Pharmaceuticals Ltd. does not currently pay dividends.
What is Recce Pharmaceuticals Ltd.’s EPS estimate?
Recce Pharmaceuticals Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Recce Pharmaceuticals Ltd. have?
Recce Pharmaceuticals Ltd. has 289,183,400 shares outstanding.
What happened to Recce Pharmaceuticals Ltd.’s price movement after its last earnings report?
Recce Pharmaceuticals Ltd. reported an EPS of -AU$0.057 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.917%.
Which hedge fund is a major shareholder of Recce Pharmaceuticals Ltd.?
Currently, no hedge funds are holding shares in AU:RCE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recce Pharmaceuticals Ltd. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
38.63%
12-Months-Change
Fundamentals
Return on Equity
279.21%
Trailing 12-Months
Asset Growth
-51.48%
Trailing 12-Months
Company Description
Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd operates as a biotechnology enterprise, concentrating on the research, advancement, and market introduction of synthetic anti-infective treatments across Australia, the United States, and the United Kingdom. The company's foremost developmental drug, RECCE 327, is intended to address blood infections and sepsis caused by E. coli and S. aureus bacteria, including their antibiotic-resistant variants. Additionally, Recce is progressing RECCE 529, a synthetic anti-infective targeting viral illnesses, and RECCE 435, another synthetic polymer anti-infective. Founded in 2007, the firm, which was initially named Recce Limited, officially became Recce Pharmaceuticals Ltd in November 2017. Its corporate headquarters are situated in Sydney, Australia.
Technical Analysis
Amplia Therapeutics
―
Imugene
―
Alterity Therapeutics
―
Prescient Therapeutics Limited
―
Arovella Therapeutics Limited
―
Options Prices
Currently, No data available
---